Info

🌱 來自：Antibody Drug Conjugates

Polatuzumab vedotin

• Mechanism:
  • Anti-CD79b humanized IgG1;
  • after binding,
    • releases antimicrotubule agent MMAE,
    • producing cell cycle arrest & apoptosis
• Approved indication: Diffuse large B-cell lymphoma
• Dosing:
  • 1.8 mg/kg IV every 21 d;
  • avoid use in mod./sev. hepatic impairment;
  • no adjustment for mild/mod. renal impairment;
  • manufacturer-recommended dose reductions available for hematologic toxicity, neuropathy
• PK/PD:
  • T1/2 12 d for ADC, 4 d for MMAE;
  • MMAE metabolized hepatically (CYP3A4)
• AEs:
  • Myelosuppression,
  • neuropathy,
  • diarrhea,
  • low emetogenicity,
  • infusion rxns,
  • infxns
• DDI:
  • Strong CYP3A4 inhibitors/inducers likely increase/decrease MMAE exposure;
  • no specific dose adjustments recommended;
  • MMAE is a P-glycoprotein substrate
• Clinical pearls:
  • HSV/VZV & PJP prophylaxis required,
  • consider 1° GCSF prophylaxis